Eased lockdowns and lifted restrictions have placed significant pressure on the global drug pipeline.
The global pandemic, which has affected more than 5.5 million, is forcing drugmakers and biotech firms of all sizes to shorten the timeline for a vaccine, which is essential to easing fears about returning to work and school. To-date, nearly a dozen companies in the U.S., Europe and China have started human trials for more than 100 vaccine candidates.
Most recently, Novavax (NVAX) announced it would begin human trials, for its coronavirus vaccine, making it the fourth company in the U.S. to do so. The biotech company is starting its clinical trials in Australia, and intends to produce 100 million doses by the end of the year and a billion doses in 2021.
Meanwhile, Merck (MRK), one of the largest players in the vaccine race, finally unveiled details of its efforts Tuesday. The company announced